Profound Medical showcased clinical data and software upgrades for its TULSA prostate treatment system at a recent conference. CAPTAIN-era data showed TULSA patients returned to work faster than robotic prostatectomy patients (10 versus 19 days) with zero hospitalisations versus over 6%. The company is scaling AI tools including Thermal Boost Contouring Assistant and partnering with Siemens and Cook on compact interventional MRI systems. Revenue grew from approximately CAD 10 million in 2024 to CAD 16 million in 2025, with management projecting high double-digit growth and potential profitability at around 200 sites. TULSA uses MRI-guided ultrasound ablation without incisions, positioning itself between robotic prostatectomy and focal therapy. The company estimates a 600,000-patient addressable market with roughly $500,000 capital costs plus $5,500 per-patient disposables.

Profound Medical reported Q4 2025 revenue of $6.0 million, a 43% year-on-year increase, comprising $2.3 million in recurring revenue and $3.7 million from capital equipment sales. Gross margin declined to 67% from 71% the previous year, whilst the company posted a net loss of CAD 8.2 million with CAD 59.7 million cash on hand. The company announced completion of recruitment and treatments for its CAPTAIN trial, comparing its technology to robotic radical prostatectomy for localised prostate cancer. Primary safety and quality-of-life endpoints will be presented at the European Association of Urology meeting on 13 March. Profound ended 2025 with 78 TULSA-PRO sites and a 110-system pipeline, targeting profitability around $80-85 million revenue.

INOVAIT honors Profound with 2025/26 Mount Logan Award recognizing tulsa procedure for prostate disease. February 12, 2026 Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that it has received the 2025/2026 Mount Logan Award from INOVAIT, the Canadian national network for commercializing breakthroughs in image-guided therapy and AI. In a statement, Raphael Ronen, co-executive director of INOVAIT, commented, "The Mount Logan Award recognizes an INOVAIT industry member who has consistently exceeded project milestone expectations, reached new heights as a Canadian company, and stood out internationally. Profound Medical has achieved significant milestones and international acclaim over the last year, including treating their 4,000th TULSA Procedure patient, securing new U.S. reimbursement codes from Medicare, and establishing strategic partnerships to expand patient access globally, and is, therefore, worthy of celebrating with the Mount Logan Award." The iMRI TULSA Procedure, performed using the TULSA-PRO system, represents a major advancement in prostate care, and is used by physicians to treat men with prostate cancer and/or benign prostatic hyperplasia (BPH, also known as an enlarged prostate). Robotically controlled directional ultrasound is delivered from inside the urethra to precisely and gently heat prostate tissue to 'kill temperature' (55-57°C), while protecting surrounding nerves and anatomy. Real-time MRI thermography enables continuous visualization and autonomous temperature adjustment throughout the procedure. This level of precision allows physicians to tailor therapy to each patient, resulting in no procedural blood loss, no overnight hospital stay, and a quicker return to everyday life, while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction. Arun Menawat, CEO and chairman of Profound, remarked, "We are incredibly honored to receive this award as we work to drive widespread global commercialization of a home-grown Canadian medical innovation. While currently only one TULSA-PRO system install resides in Canada, we hope to change that moving forward as we just recently regained exclusive distribution rights in the country from a previous partner. In the meantime, the importance of that single current commercial placement in Canada can't be overstated. Toronto's renowned Sunnybrook Health Sciences Centre, the original innovator of the TULSA-PRO technology, has already performed more than 100 TULSA Procedures despite it not being covered by a provincial health insurance plan. Moving forward, as user interest in Profound's technologies continues to build, we are deploying our own direct sales team in North America, while partnering with select strategic distribution partners to support the business potential and the customer base in other parts of the world." Mathieu Burtnyk, president of Profound, added, "We are deeply grateful to INOVAIT for supporting a vision where AI enabled, image guided therapies like TULSA-PRO are not only developed in Canada, but lead the world. That support gives companies like ours the momentum to turn bold ideas into real clinical impact."